Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity

Value in Health

Volumn 11, Issue 4, 2008, Pages 563-574

  Javitt, Jonathan C ^a,b,c   Zlateva, Gergana P ^d   Earnshaw, Stephanie R ^e   Pleil, Andreas M ^d   Graham, Christopher N ^e   Brogan, Anita J ^e   Shah, Sonali N ^d   Adamis, Anthony P ^f  

^a Potomac Institute for Policy Studies ^*  (United States)

^b POTOMAC INSTITUTE FOR POLICY STUDIES   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d PFIZER INC   (United States)

^e RTI HEALTH SOLUTIONS   (United States)

^f OSI PHARMACEUTICALS INC   (United States)

Author keywords

Age related macular degeneration; Cost effectiveness; Markov model; Pegaptanib

Indexed keywords

PEGAPTANIB;

AGED; ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; EARLY INTERVENTION; ENDOPHTHALMITIS; HUMAN; LENS DISEASE; MAJOR CLINICAL STUDY; MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RESOURCE MANAGEMENT; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; THERAPY DELAY; VISUAL ACUITY;

EID: 47749151493     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00283.x     Document Type: Article

References (43)

1. Gottlieb JL. Age-related macular degeneration. JAMA 2002 288 : 2233 6.
2. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004 122 : 564 72.
3. Chia EM, Wang JJ, Rochtchina E, et al. Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004 45 : 71 6.
4. Coleman AL, Stone K, Ewing SK, et al. Higher risk of multiple falls among elderly women who lose visual acuity. Ophthalmology 2004 111 : 857 62.
5. Ivers RQ, Cumming RG, Mitchell P, et al. Visual risk factors for hip fracture in older people. J Am Geriatr Soc 2003 51 : 356 63.
6. Legood R, Scuffham P, Cryer C. Are we blind to injuries in the visually impaired? A review of the literature. Inj Prev 2002 8 : 155 60.
7. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001 108 : 1893 900.
8. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol 2002 120 : 1041 4.
9. Wang JJ, Mitchell P, Cumming RG, Smith W. Visual impairment and nursing home placement in older Australians: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003 10 : 3 13.
10. Brown MM, Brown GC, Sharma S, et al. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol 2006 17 : 257 66.
11. Soubrane G, Cruess A, Lotery A, et al. Burden and resource utilization of neovascular AMD: findings of a multicountry study. Arch Ophthalmol 2007 125 : 1249 54.
12. Stein JD, Brown MM, Brown GC, et al. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol 2003 87 : 8 12.
13. Mangione CM, Gutierrez PR, Lowe G, et al. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol 1999 128 : 45 53.
14. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001 108 : 2051 9.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 351 : 2805 16.
16. Gonzales CR, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005 25 : 815 27.
17. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetes. Ophthalmology 1989 96 : 255 64.
18. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries: costs are greater for those with progressive vision loss. Ophthalmology 2007 114 : 238 45.
19. Deramo VA, Cox TA, Syed AB, et al. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003 121 : 1297 302.
20. Augood C, Fletcher A, Bentham G, et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol 2004 11 : 117 29.
21. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997 104 : 7 21.
22. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 1996 103 : 357 64.
23. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991 7 : 403 22.
24. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006 113 : 1508 21.
25. D'Amico DJ, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006 113 : 992 1001.
26. US Census Bureau Public Information Office. United States Census 2000 Summary File 1 (SF1). Washington, DC : US Census Bureau Public Information Office, 2005.
27. Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2002 108 : 1767 79.
28. Olsen TW, Feng X, Kasper TJ, et al. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004 111 : 250 5.
29. Hoyert DL, Heron MP, Murphy SL. Deaths: Final Data for 2003. National Vital Statistics Reports (vol. 54 no. 13). Hyattsville, MD : National Center for Health Statistics, 2006.
30. Zhou S, Javitt JC, Zlateva G, Shah SN. Evaluating the risk of mortality for exudative (wet) AMD patients compared to a control group. Invest Ophthalmol Vis Sci 2006 47 : E abstract 2213.
31. Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. Br J Ophthalmol 2004 88 : 212 17.
32. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000 118 : 47 51.
33. Quarterly Average Sale Price (ASP) Medicare Part B Drug Pricing File, Effective October 1, 2005 (CR 3992, Pub. 100-04. Rev. 653).
34. The Essential RBRVS: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes. Salt Lake City, UT : Ingenix, Inc., 2005.
35. U.S. Department of Labor: Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers (Current Series). March 2006. Available from: http://data.bls.gov/PDQ/outside.jsp?survey=cu [Accessed March 13, 2006].
36. The MetLife Market Survey of Nursing Home and Home Care Costs. Westport, CT : MetLife Mature Market Institute, 2004.
37. ® versus no treatment in age-related macular degeneration patients. Invest Ophthalmol Vis Sci 2006 47 : E Abstract 1135.
38. Earnshaw S, Javitt J, Zlateva G, et al. Cost-effectiveness model for age-related macular degeneration: comparing Macugen to Visudyne. Value Health 2005 8 : 176A 7A.
39. Sharma S, Bakal J, Sharma SM, et al. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005 40 : 369 77.
40. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - a value-based reappraisal with 5-year data. Am J Ophthalmol 2005 140 : 679 87.
41. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003 7 : 1 98.
42. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003 6 : 9 17.
43. Bandello F, Lafuma A, Berdeaux G. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Invest Ophthalmol Vis Sci 2007 48 : 96 103.